Trial Profile

Dendritic cells loaded with allogeneic tumor cell lysate (PheraLys) in surgically resected pancreatic cancer patients (REACtiVe Trial)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Autologous dendritic cell vaccine Amphera (Primary) ; Autologous dendritic cell vaccine Amphera (Primary)
Indications Adenocarcinoma; Pancreatic cancer
Focus Therapeutic Use
Acronyms REACtiVe

25 Sep 2024 According to an Amphera media release, Prof Casper van Eijck, pancreatic cancer surgeon, Erasmus MC in Rotterdam is the principal investigator of this trial.
25 Sep 2024 According to an Amphera media release, primary end point (Clinically significant increase in 2-year recurrence-free survival) has been met.
25 Sep 2024 According to an Amphera media release, EMA and FDA have granted MesoPher Orphan Designation for pancreatic cancer, based on potential significant benefit.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com